MedTrace Logo

Analysis of Circulating Exosomes in Melanoma Patients

NCT05744076 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-02-24

No results posted yet for this study

Summary

The hypothesis is that PD-L1\[Programmed Death-Ligand 1\] labeling in exosomes could be a biomarker of disease progression in melanoma. The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.

Conditions

Sponsors & Collaborators

  • Centre Georges Francois Leclerc

    collaborator OTHER

  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05744076 on ClinicalTrials.gov